Cangene’s Antidote for Terrorism Toxin Works, FDA Staff Says

Cangene Corp.’s animal studies on an experimental antidote for a toxin considered a bioterrorism threat are sufficient enough to suggest the treatment will work in humans, U.S. regulators said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.